Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.


Houda Boukhebza, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article
Publication

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11

 

© 2018 Transgene - All rights reserved
Mentions légales - Crédits